This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Early Allergy Season: Sneezing Your Way to Profit




By Stephanie Landsman, Producer, "Squawk Box"

NEW YORK ( CNBC) --While allergy sufferers pay the price for a warmer than usual winter, profits will likely bloom for pharmaceutical companies. So stop and smell the roses. This could provide a healthy boost to your portfolio.

It's only March and pollen counts are setting record highs all over the Southeast. In New York City, trees are blooming several weeks ahead of schedule.

"An early start to the allergy season is always good for the large pharmaceutical companies that manufacture allergy meds," said Paul Walsh, vice president of weather analytics at the Weather Channel. "This year's mild winter followed by record spring warmth is manna from heaven for these firms." (Note: The Weather Channel is owned by NBCUniversal, CNBC's corporate parent.)

More from CNBC
'Solar Flare-Ups': Petitions Over UFOs and Weather Cuts
Did a Tax-Budget Battle Almost Kill the US in 1812?
Hamptons 'Beach Pass Barometer': Economic Rebound Sign?

So, we're sniffing out new portfolio strategies in between sneezing and wheezing.

"The early onset of the allergy season could provide a boost to an industry that missed out on a big flu season," said Argus Research President John Eade.

Eade, who follows big pharma, said the timing of this season could also aid Merck (MRK) -- which is the biggest seller of prescription allergy medicine. That's because it loses its patent protection on its blockbuster drug Singulair later this year. When Merck does, Eade said Mylan Labs (MYL) is in line to launch a generic.

"Other companies positioned to profit are the diversified pharma companies that own consumer products divisions -- including Johnson & Johnson and Pfizer," said Eade.

Miller Tabak Health Care Transformation Fund Manager Les Funtleyder shares the same view.

"We kind of had for drug companies not a great cold and flu season, because the weather was so wrong for it. But, we'll make it back on the allergies," said Les Funtleyder.

Merck, Johnson & Johnson (JNJ), Sanofi (SNY) and Pfizer (PFE) make a big portion of the allergy drugs in the market -- both prescription and over-the-counter. Of those, Funtleyder believes Merck, the maker of the antihistamine Claritan and nasal spray Afrin, will be the biggest winner.

Bottom line: You may not be breathing easier, but the world's biggest pharmaceutical companies will be, this spring.

Disclosure: Miller Tabak Health Care Transformation Fund owns shares Of Merck and Johnson & Johnson.



--Written by Stephanie Landsman at CNBC.

CNBC is a world leader in business news, providing real-time financial market coverage and business information.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $126.41 -1.66%
FB $81.21 0.39%
GOOG $575.33 0.34%
TSLA $200.63 -0.89%
YHOO $44.16 0.39%

Markets

DOW 18,135.72 +38.82 0.21%
S&P 500 2,101.04 +2.51 0.12%
NASDAQ 4,982.8090 +15.6680 0.32%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs